Novartis' hot new eye drug Beovu tied to potential vision lo
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk when it comes to prescribing the medicine.

The American Society of Retina Specialists (ASRS) issued a note Sunday night to members about 14 cases of retinal vasculitis for Beovu patients, 11 of which were occlusive retinal vasculitis that can lead to vision loss, Piper Sandler analyst Christopher Raymond wrote in a Monday note to clients.

That's a side effect that so far hasn't plagued other drugs in the anti-VEGF class, which includes Regeneron's Eylea. One doctor told Raymond "his entire practice would not be ordering Beovu, but anyone who has, should likely 'freak out' upon reading" the ASRS communication, the analyst wrote.

Novartis, meanwhile, has "engaged an external safety review committee to further evaluate these post-marketing cases," a spokesman said, adding that the drugmaker would also do its own internal assessment. "Patient safety is of paramount importance," he said, adding that "we will continue to share details as they become available."

Beovu, which won approval in October to treat wet age-related macular degeneration, represents a critical new launch for Novartis in a competitive field.
Of course, the alert is “fresh” and that’s only one doctor’s opinion, Raymond stressed.

Source : https://pxmd.co/H9AsU
Like
Comment
Share